Skip to main content

RayzeBio, Inc.

RYZBDelisted Feb 26, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001825367

RayzeBio, Inc. was delisted on Feb 26, 2024; its insiders filed their last Form 4 on Feb 28, 2024; 107 institutions reported holding it in 13F filings for Q4 2023, worth $3.40B in total; superinvestors Viking Global Investors and HHLR Advisors (Hillhouse) held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by RayzeBio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for RayzeBio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for RayzeBio, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Viking Global Investors LP10% Owner0IndirectFeb 28, 20240
Halvorsen Ole Andreas10% Owner0IndirectFeb 28, 20240
Ott David C.10% Owner0IndirectFeb 28, 20240
Shabet Rose Sharon10% Owner0IndirectFeb 28, 20240
Viking Global Opportunities Parent GP LLC10% Owner0IndirectFeb 28, 20240
Viking Global Opportunities Drawdown Portfolio GP LLC10% Owner0IndirectFeb 28, 20240
Viking Global Opportunities Drawdown GP LLC10% Owner0IndirectFeb 28, 20240
Viking Global Opportunities Drawdown (Aggregator) LP10% Owner0IndirectFeb 28, 20240
Viking Global Opportunities Portfolio GP LLC10% Owner0IndirectFeb 28, 20240
Viking Global Opportunities GP LLC10% Owner0IndirectFeb 28, 20240
Viking Global Opportunities Illiquid Investments Sub-Master LP10% Owner0IndirectFeb 28, 20240
Tagliaferri MaryDirector–Feb 27, 20240
Heyman Richard A.Director0Feb 27, 20240
Song KennethPRESIDENT AND CHIEF EXECUTIVE0IndirectFeb 27, 20240
You AngieDirector–Feb 27, 20240
Katabi MahaDirector0IndirectFeb 27, 20240
Larson YiDirector–Feb 27, 20240
Van Hauwermeiren TimothyDirector–Feb 27, 20240
Oliger Christy J.Director–Feb 27, 20240
Moran SusanCHIEF MEDICAL OFFICER0Feb 27, 20240
Kush ArvindCHIEF FINANCIAL OFFICER0Feb 27, 20240
Redmile Group, LLC10% Owner1,857,706IndirectSep 21, 20230
Green Jeremy10% Owner1,857,706IndirectSep 21, 20230
Redmile Biopharma Investments II, L.P.10% Owner1,857,706IndirectSep 21, 20230
Goodman Corey S10% Owner5,158,162Sep 21, 20230
Adelman Robert J10% Owner5,158,162Sep 21, 20230
venBio Global Strategic Fund III, L.P.10% Owner5,158,162Sep 21, 20230
Venbio Global Strategic GP III, Ltd10% Owner5,158,162Sep 21, 20230
Venbio Global Strategic GP III, L.P.10% Owner5,158,162Sep 21, 20230
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.10% Owner1,557,846Sep 19, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 21, 2023 (view filing)5:00 PM ETSep 192 daysViking Global Investors LP and 7 others10% OwnerPPurchase+1.39M$18.00+$25.0M+391.6%1.74M after2 lotsDuplicate filing
Sep 21, 2023 (view filing)4:59 PM ETSep 192 daysViking Global Investors LP and 7 others10% OwnerPPurchase+1.39M$18.00+$25.0M+391.6%1.74M after2 lots
Sep 21, 2023 (view filing)Sep 192 daysKatabi MahaDirectorPPurchase+472.2K$18.00+$8.50M+64.0%1.21M after2 lots